Screening for prostate cancer
173 results
101 - 173
5‐alpha‐reductase inhibitors for prostate cancer prevention
Five-alpha-reductase inhibitors for prostate cancer prevention 
Need to screen 1055 and treat 37 to prevent one prostate CA death over 11 years (ERSPC)- ACP: Discuss prostate screening with men 50-69 years old
- Observation = radical prostatectomy for most pts with localized prostate cancer (PIVOT)
- PSA plus MRI-guided biopsy reduces the detection of clinically insignificant prostate cancers more than systematic biopsy
- PSA screening has marginal effect on mortality in European study (ERSPC)
- Radical prostatectomy versus watchful waiting for newly diagnosed prostate cancer
- Screening for ovarian cancer with CA-125/ultrasound algorithm does not reduce mortality (UKCTOCS)
- Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality
- Prostatectomy reduces mortality compared with no surveillance in men with T2 cancer who presented with symptoms
- USPSTF: No PSA screening in men 75 years and older
- Impact of PSA screening on quality of life
- For men with PSA > 3.0, limiting biopsy to lesions seen on MRI appears to be safe
- Benign prostatic hyperplasia
- Annual screening chest x-ray does not reduce lung cancer mortality
- PSA screening does not decrease mortality
- Treatment for symptom-detected early prostate CA effective in pts younger than 65
- Low-intensity PSA-based screening does not reduce mortality, but leads to overdiagnosis and potential harm
- High false positive rate in repeated, multimodal screening for cancers (PLCO)
- Modelling study shows less-intense screening is okay for men with low baseline PSA levels
- Lycopene for the prevention of prostate cancer
- Patients experience shame and isolation for deciding not to pursue thyroid cancer treatment
- Mammography identifies many women who will not benefit from treatment
- Active surveillance reduces the need for surgery, with no change in mortality, at the price of a small increase of metastatic disease (ProtecT)
- Screening for testicular cancer
- Bisphosphonates for advanced prostate cancer
- Flex sig reduces incidence and mortality of colorectal cancer
- Ovarian cancer screening does not improve outcomes (UKCTOCS)
- Haematuria
- Radical prostatectomy versus deferred treatment for localised prostate cancer
- Primary cryotherapy for localised or locally advanced prostate cancer
- Psychosocial interventions for men with prostate cancer: Cochrane systematic review
- Likelihood of most adverse treatment outcomes lowest with active surveillance of clinically localized prostate CA (ProtecT)
- Population screening for cancer
- Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
- Navigation program slightly decreases time to resolution of abnormal cancer screening results
- Routine CT scans for occult malignancy not useful in patients with unprovoked VTE
- Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer
- Hereditary susceptibility to cancer
- Government regulation of private health insurance
- Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery: Cochrane systematic review
- Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
- Personalised risk communication for informed decision making about taking screening tests: Cochrane systematic review
- Limited evidence of benefits of vitamin D supplementation
- Testosterone gel has little, if any, benefit for older men with hypogonadism
- Decision aids for people facing health treatment or screening decisions
- Interventions for promoting habitual exercise in people living with and beyond cancer
- Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults
- Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
- Myositis
- Interventions for managing medication‐related osteonecrosis of the jaw
- Green and black tea for the primary prevention of cardiovascular disease: Cochrane systematic review
- Penile rehabilitation for postprostatectomy erectile dysfunction